Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation reports news on its Omnipod product platform for diabetes care, including the Omnipod Insulin Management System and Omnipod 5 Automated Insulin Delivery System. The company’s tubeless disposable Pods provide up to three days of insulin delivery, while Omnipod 5 integrates with continuous glucose monitors and can be controlled through a compatible smartphone in the U.S. or through the Omnipod 5 Controller.
Recurring Insulet developments include quarterly results, Omnipod revenue trends, sensor-connectivity updates, clinical evidence for automated insulin delivery, and research involving fully closed-loop systems for type 2 diabetes. Company updates also cover medical device corrections, product quality actions, executive appointments, conference presentations, and the use of Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet (NASDAQ: PODD) reported Q1 2026 revenue of $761.7 million, up 33.9% (30.1% constant currency). Total Omnipod revenue was $758.4 million. GAAP net income was $91.1 million ($1.30 diluted EPS); adjusted net income was $99.8 million ($1.42 adjusted EPS).
The company raised full‑year revenue guidance, noted margin expansion, launched Omnipod 5/Discover in five Middle East countries, advanced AID clinical programs, repurchased 1.25 million shares, and provided Q2 and FY 2026 constant‑currency guidance.
Insulet (NASDAQ: PODD) published its 2025 Sustainability Report highlighting progress across operations, products, people, and community. Key metrics: 13% of global electricity from renewables, 24% Malaysia site on onsite solar, 8.9 million Pods accepted, and 23% reduction in baseline packaging weight. The report also expands U.S. Pod recycling to all 50 states and DC and reports 2,900+ employee volunteer hours through Insulet for Good.
Insulet (NASDAQ: PODD) enrolled the first participant in the EVOLVE pivotal randomized control trial of a fully closed-loop automated insulin delivery (FCL AID) system for type 2 diabetes. The multi-center U.S. study may enroll up to 350 adults and follows FDA IDE approval in March 2026.
Insulet reported prior feasibility and SECURE-T2D results showing improved time-in-range and lower HbA1c, and plans a 510(k) filing in 2027 with an expected launch in 2028.
Insulet (NASDAQ: PODD) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. PT. A live webcast and replay will be available on the Insulet investor relations website.
The presentation covers company updates and the Omnipod product platform; webcast access: investors.insulet.com/events.
Insulet (NASDAQ: PODD) announced it will report first quarter 2026 financial results on Wednesday, May 6, 2026, before the opening of U.S. markets. Management will host a conference call at 8:00 a.m. Eastern Time that day and a live webcast will be available.
Investors can join via the Investor Relations "Events and Presentations" page, or by dialing the provided domestic and international numbers using passcode 5904836. The webcast will be archived for future replay. The company markets the Omnipod tubeless insulin pump platform and Omnipod 5 automated insulin delivery system.
Insulet (NASDAQ: PODD) appointed Mike Panos as Executive Vice President, Chief Commercial Officer, effective March 30, 2026. Mr. Panos will lead the company’s global commercial organization and report to President and CEO Ashley McEvoy as a member of the Executive Leadership Team.
He brings 30 years of medical-technology commercial leadership, most recently at Stryker, and will focus on commercial strategy, market access, and expansion into new patient populations and care settings to support growth of the Omnipod platform.
Insulet (NASDAQ: PODD) initiated a voluntary Medical Device Correction on March 12, 2026 for specific Omnipod 5 Pod lots distributed in the U.S. Certain Pods may have a small tear in internal tubing causing insulin to leak and possible under-delivery.
Insulet reported 18 serious adverse events including hospitalization and DKA, no deaths, updated manufacturing controls, said affected pods are ~1.5% of annual production, and offers free replacement Pods via omnipod.com/check-pods.
Insulet (NASDAQ: PODD) presented EVOLUTION 2 feasibility study results for its investigational Omnipod fully closed-loop (FCL) automated insulin delivery system for adults with type 2 diabetes.
In 24 diverse adults using the final algorithm with no boluses, average time in range reached 68% (a 24% improvement versus injection therapy); median time below range was 0.14%. No severe hypoglycemia or DKA occurred. Over 90% of participants continued into the extension. The company plans a pivotal EVOLVE study in 2026, a 510(k) filing in 2027, and commercial launch in 2028.
Insulet (NASDAQ: PODD) will present EVOLUTION 2 results for its Omnipod fully closed-loop automated insulin delivery system for adults with type 2 diabetes at ATTD 2026 in Barcelona, March 11–14, 2026.
The company will host a symposium on March 11 (2:40–4:10 p.m. CET, Hall 112), present seven posters/orals including e-Poster EP070, and offer product demos, an immersive education HUB, live podcasts, and a March 13 webcast recap at 3:00 PM CET.
Insulet (NASDAQ: PODD) reported strong Q4 2025 and full‑year results: Q4 revenue $783.8M (+31.2%) and FY 2025 revenue $2.7B (+30.7%); gross margin improved to 72.5% in Q4 and 71.6% for the year. The company announced a $350M increase in its share repurchase authorization and provided 2026 guidance with mid‑20s revenue growth in constant currency.
Insulet highlighted >600,000 estimated active Omnipod users, international expansion, FDA algorithm enhancements for Omnipod 5, and stronger operating cash flow and free cash flow versus prior year.